SCHEMBL9942738

SCHEMBL9942738

CCN(C(=O)c1ccc(-c2ccccc2)cc1OC)c1c[nH]c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.46
CDK4 P11802 4/20 0.44
CCND1 P24385 4/20 0.44
USP2 O75604 2/20 0.43
MAPT P10636 4/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
GAA P10253 2/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.42
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42
FPR1 P21462 1/20 0.41
CDK2 P24941 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3800066 0.77 MEN1 (0.40) NR4A2CDK4CCND1MAPTKDM4E
SCHEMBL3801993 0.76 NPC1 (0.52) CDK4CCND1MAPTKMT2AMEN1
SCHEMBL6394938 0.74 ALDH1A1 (0.56) CDK4MAPTHPGDKDM4ESMN1; SMN2
SCHEMBL7585320 0.74 ALDH1A1 (0.52) NR4A2CDK4CCND1MAPTHPGD
SCHEMBL3866597 0.74 OXTR (0.44) NR4A2MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL3797880 0.72 ALDH1A1 (0.41) CDK4CCND1MAPTKDM4ESMN1; SMN2
SCHEMBL27474102 0.71 LMNA (0.58) NR4A2MAPTHPGDKDM4ESMN1; SMN2
SCHEMBL3804572 0.71 ALDH1A1 (0.44) CDK4CCND1MAPTKDM4ESMN1; SMN2
SCHEMBL3805967 0.71 ALDH1A1 (0.43) NR4A2MAPTHPGDKDM4ESMN1; SMN2
SCHEMBL26978217 0.70 ALDH1A1 (0.51) MAPTHPGDKDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651887-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
WO-2012080220-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed